ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2020; 11(10):2800-2807. doi:10.7150/jca.41122 This issue Cite
Research Paper
Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer
1. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2. Division of Hematology and Oncology, Department of Internal Medicine, National Medical Center, Seoul, Korea.
3. Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea
4. Department of Thoracic Surgery, Kyung Hee University Hospital at Gangdong, Seoul, Korea
Citation:
Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer 2020; 11(10):2800-2807. doi:10.7150/jca.41122. https://www.jcancer.org/v11p2800.htm
Other stylesAbstract
Objectives: Several factors associated with the prognosis of patients with NSCLC have been reported in the literature; however, most of these factors cannot be examined preoperatively. In this study, the clinical utility of platelet parameters in patients with NSCLC who underwent curative resection was evaluated.
Materials and Methods: A retrospective study on patients with NSCLC who underwent curative resection from July 2006 to September 2016 was conducted. The Cox proportional hazard regression model was applied to evaluate the variables that demonstrated effects on disease-free and overall survival (DFS and OS).
Results: A total of 116 patients with NSCLC were analyzed. There were 15 patients with plateletcrit greater than 0.2755%, and 101 patients whose plateletcrit was 0.2755% or lower. Multivariate analysis identified plateletcrit higher than 0.2755% (hazard ratio [HR] = 4.18, 95% confidence interval [CI] = 1.54-11.34, P =0.004), patient age of 65 years or more (HR = 4.02, 95% CI = 1.67-9.66, P = 0.001), and stage II or IIIA disease (HR = 2.95, 95% CI = 1.26-6.87, P = 0.012) as independent factors for OS that predicted a poor prognosis. Multivariate analysis identified plateletcrit higher than 0.2755% (HR = 4.07, 95% CI = 1.52-10.94, P = 0.005), stage II or IIIA disease (HR = 5.38, 95% CI = 2.71-10.66, P < 0.001) and non-adenocarcinoma (HR = 1.92, 95% CI = 1.02-3.59, P = 0.040) as independent prognostic factors for DFS that predicted a poor prognosis.
Conclusion: Our results suggest a potential role of preoperative plateletcrit as an independent prognostic marker for patients with resectable NSCLC.
Keywords: plateletcrit, non small cell lung cancer, mean platelet volume.
Citation styles
APA
Hur, J.Y., Lee, H.Y., Chang, H.J., Choi, C.W., Kim, D.H., Eo, W.K. (2020). Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. Journal of Cancer, 11(10), 2800-2807. https://doi.org/10.7150/jca.41122.
ACS
Hur, J.Y.; Lee, H.Y.; Chang, H.J.; Choi, C.W.; Kim, D.H.; Eo, W.K. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J. Cancer 2020, 11 (10), 2800-2807. DOI: 10.7150/jca.41122.
NLM
Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer 2020; 11(10):2800-2807. doi:10.7150/jca.41122. https://www.jcancer.org/v11p2800.htm
CSE
Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. 2020. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer. 11(10):2800-2807.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.